New insider activity at Myomo ( (MYO) ) has taken place on August 18, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CEO Paul R. Gudonis has made a significant investment in Myomo by purchasing 50,000 shares of the company’s stock, valued at $47,000.
Recent Updates on MYO stock
In the last 24 hours, Myomo Inc’s stock has seen significant developments following the release of its Q2 2025 earnings report. The company reported a 28% increase in revenue to $9.7 million, surpassing expectations. However, challenges in lead quality and pipeline conversion were noted, leading to strategic shifts in advertising and healthcare professional engagement. These factors, along with increased operating expenses and a decline in gross margin, prompted analysts to lower price targets. H.C. Wainwright reduced its target due to a lower-than-expected patient pipeline, while Alliance Global Partners and Craig-Hallum also adjusted their targets based on the company’s revised revenue guidance of $40M-$42M for 2025, down from $50M-$53M. Myomo is focusing on improving lead quality and expanding its network of healthcare providers to drive future growth.
Spark’s Take on MYO Stock
According to Spark, TipRanks’ AI Analyst, MYO is a Neutral.
Myomo’s overall stock score is primarily impacted by its financial performance challenges, including negative margins and cash flows. Technical analysis indicates bearish momentum, further weighing down the score. While the earnings call and corporate events provide some positive outlooks, they are not sufficient to offset the financial and technical weaknesses.
To see Spark’s full report on MYO stock, click here.
More about Myomo
YTD Price Performance: -84.95%
Average Trading Volume: 841,717
Technical Sentiment Signal: Sell
Current Market Cap: $36.86M